Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -783.01% is 37% above its 5-year average of -1239.22%, near the high end of its 5-year range (-4547.80%–-244.64%).
13.62% below its 12-month average of -689.15%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -244.64%.
EBITDA MARGIN
-783.01%
EBITDA MARGIN AVG TTM
-689.15%
EBITDA MARGIN AVG 3Y
-1010.66%
EBITDA MARGIN AVG 5Y
-1239.22%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-13.62%
CURRENT VS 3Y AVG
+22.52%
CURRENT VS 5Y AVG
+36.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Nyxoah S.A.
Market Cap
$144.10M
EBITDA Margin
-783.01%
TTM Avg
-689.15%
3Y Avg
-1010.66%
5Y Avg
-1239.22%
Market Cap
$144.84M
EBITDA Margin
-239.78%
TTM Avg
-210.59%
3Y Avg
-2213.91%
5Y Avg
-2345.87%
Market Cap
$142.85M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
Market Cap
$142.40M
EBITDA Margin
-95.26%
TTM Avg
-233.98%
3Y Avg
-174.91%
5Y Avg
-167.88%
Market Cap
$147.71M
EBITDA Margin
-550.97%
TTM Avg
-275.49%
3Y Avg
-275.49%
5Y Avg
-275.49%
Market Cap
$148.31M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
Market Cap
$139.73M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$139.16M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nyxoah S.A. (NYXH) | $144.10M | -783.01% | -689.15% | -1010.66% | -1239.22% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.84M | -239.78% | -210.59% | -2213.91% | -2345.87% |
| Immuneering Corporation (IMRX)vs › | $142.85M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| Sutro Biopharma, Inc. (STRO)vs › | $142.40M | -95.26% | -233.98% | -174.91% | -167.88% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $147.71M | -550.97% | -275.49% | -275.49% | -275.49% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | -0.19% | -1.66% | -11.02% | -42.72% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | -103.63% | -143.63% | -176.25% | -194.05% |
| Alpha Cognition Inc (ACOG)vs › | $139.16M | -221.15% | -221.15% | -221.15% | -221.15% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $149.18M | N/A | N/A | N/A | N/A |
Gross Margin
63.1%
EBITDA Margin
-783.0%
Operating Margin
-827.8%
Net Margin
-435.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -244.64% |
| 2026-03-31 | -295.42% |
| 2025-12-31 | -297.01% |
| 2025-09-30 | -1153.90% |
| 2025-06-30 | -1454.78% |
| 2025-03-31 | -1905.64% |
| 2024-12-31 | -1390.10% |
| 2024-09-30 | -1156.87% |
| 2024-06-30 | -1640.34% |
| 2024-03-31 | -950.29% |
| 2023-12-31 | -554.44% |
| 2023-09-30 | -1072.44% |
| 2023-06-30 | -1022.67% |
| 2023-03-31 | -2458.28% |
| 2022-12-31 | -654.71% |
| 2022-09-30 | -4547.80% |
| 2022-06-30 | -739.68% |
| 2022-03-31 | -1033.03% |
| 2021-12-31 | -2065.08% |
| 2021-09-30 | -3775.37% |
| 2021-06-30 | -3455.88% |
| 2021-03-31 | -2674.59% |
| 2020-12-31 | -9086.96% |
| 2020-09-30 | -10394.20% |
